Biogen news and events in 2026
Biogen, Inc. is a biotechnology company that specializes in the discovery and development of therapies for neurological diseases, immunology, and rare disorders.
Public (BIIB)Biotechnology Research10,000+ employeesbiogen.comLinkedIn
Get Biogen's live signals in Claude or ChatGPT, or by API
What changed at Biogen this week? Use Autobound signals for biogen.com.- Dated updates
- 76
- Last event
- Oct 28, 2026
- Open rolesSnapshot Nov 3, 2026
- 42
- Latest SEC filing
- Oct 28, 2026
Source: Autobound Signal API · 76 signals tracked for Biogen · updated
Overview
Biogen by topic
110-K filing
42open roles
43+signals
17 in the last 90 days
- Glassdoor15+
- YouTube11
- LinkedIn9
- Patents7
- and 1 more sources
Latest events
Latest Biogen events
Showing 10 of 20 events. The Signal API returns all of them.
Get them with one API call- In developmentBiogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class...Biogen announced 52-week results from the Phase 2 part of its ongoing AMETHYST Phase 2/3 study for litifilimab, a potential first-in-class therapy for cutaneous lupus erythematosus (CLE), showing rapid and durable efficacy.
- LaunchPhase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents...Biogen announced the publication of results from a Phase 3 study of its drug EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology.
- Launch
- RecognitionCanada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s DiseaseBiogen's drug LEQEMBI® (lecanemab) received a final positive recommendation supporting public reimbursement for early Alzheimer’s disease from Canada’s Drug Agency (CDA-AMC).
- IntegrationVeeva Vault CRM Selected by BiogenWith Veeva Systems
- AcquisitionBiogen Completes Acquisition of Ray TheraBiogen has completed its acquisition of Ray Thera, a private biotechnology company, in a deal valued at up to $1 billion.
- AcquisitionBiogen Completes Acquisition of RayThera Inc.Biogen has completed its acquisition of RayThera Inc., a biotechnology company focused on immunology therapies.
- RevenueBiogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease PortfolioBiogen reported revenues of $2.736 billion, beating the consensus of $2.458 billion.
- EarningsBiogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60Biogen reported second-quarter 2026 GAAP diluted EPS of $0.66 and non-GAAP diluted EPS of $3.60.
- Partnership
Showing 10 of 20 events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Biogen with the Signal API
One POST /v1/companies/enrich call with biogen.com returns every signal type for Biogen, each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Companies related to Biogen
Biogen questions
What is the latest news on Biogen?
What is going on with Biogen?
Has Biogen announced any acquisitions?
What else does Autobound track for Biogen?
Is Biogen hiring right now?
Page updated , the date of the newest row on this page.
Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.
Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.
Data as of .